MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

Summary

This phase I trial tests the safety, side effects, and best dose of MTI-301 in treating patients with solid cancers that have spread from where they first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and that have not responded to previous treatment (refractory). MTI-301 is a drug that inhibits an enzyme called SCD1. SCD1 is an enzyme that promotes tumor growth and spread and is upregulated in some cancer types. MTI-301 may disrupt the activity of SCD1, which may lead to reduced tumor growth and/or spread.

Timeline

Start

2025-11-07

Primary completion

2027-04-09

Completion

2027-04-09

Drugs

Indications